Palmer Cody, Skroumpelos Anastasios, Sabale Ugne, Gountas Ilias, Trimis Georgios, Karokis Antonis, Agorastos Theodoros
Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
External Affairs, MSD, Athens, Greece.
Front Oncol. 2025 May 27;15:1480942. doi: 10.3389/fonc.2025.1480942. eCollection 2025.
Most cervical cancer cases are caused by human papillomavirus (HPV), a vaccine-preventable infection. According to the World Health Organization (WHO), both high HPV vaccination coverage and cervical cancer screening rates will accelerate the elimination of cervical cancer, a threshold defined as <4 age-standardized cases per 100,000 women.
A dynamic transmission model was used to study the effect of increased HPV vaccination coverage and cervical cancer screening rates in Greece on cervical cancer incidence over a 100-year time horizon. Greek-specific or proxy data were used for both model inputs and calibration prior to the evaluation of eight different vaccination and screening scenarios. The estimated time to cervical cancer elimination and eradication in Greece was reported as the year each scenario reached <4 cases per 100,000 and <1 case per 100,000, respectively.
Greece reached the WHO cervical cancer elimination threshold by 2074 with a 50% HPV vaccination coverage and 50% Pap test screening rate. When HPV DNA-based methods replaced Pap tests at the same rate and HPV vaccination coverage levels, the WHO threshold was reached by 2061. Other scenarios modeled future changes in HPV DNA-based screening rates with either 50% or 90% vaccination coverage. The 75% HPV DNA-based screening with 90% vaccination coverage scenario reached the WHO threshold by 2047 and the eradication threshold before the end of the century (2096).
If public health interventions are implemented to accelerate HPV vaccination coverage and HPV DNA-based screening adherence within the next five years, Greece can reach the WHO's cervical cancer elimination threshold by 2047 and eradicate cervical cancer before the end of the century.
大多数宫颈癌病例是由人乳头瘤病毒(HPV)引起的,这是一种可通过疫苗预防的感染。根据世界卫生组织(WHO)的数据,高HPV疫苗接种覆盖率和宫颈癌筛查率都将加速消除宫颈癌,消除宫颈癌的阈值定义为每10万名女性中年龄标准化病例数<4例。
使用动态传播模型研究希腊HPV疫苗接种覆盖率和宫颈癌筛查率的提高对100年内宫颈癌发病率的影响。在评估八种不同的疫苗接种和筛查方案之前,使用希腊特定或替代数据进行模型输入和校准。希腊消除和根除宫颈癌的估计时间分别报告为每种方案达到每10万人<4例和每10万人<1例的年份。
希腊在2074年达到了WHO的宫颈癌消除阈值,HPV疫苗接种覆盖率为50%,巴氏试验筛查率为50%。当基于HPV DNA的方法以相同比例取代巴氏试验且HPV疫苗接种覆盖率相同时,WHO阈值在2061年达到。其他方案模拟了基于HPV DNA的筛查率在疫苗接种覆盖率为50%或90%时的未来变化。疫苗接种覆盖率为90%且基于HPV DNA的筛查率为75%的方案在2047年达到WHO阈值,并在本世纪末(2096年)之前达到根除阈值。
如果在未来五年内实施公共卫生干预措施以加速HPV疫苗接种覆盖率和基于HPV DNA的筛查依从性,希腊可以在2047年达到WHO的宫颈癌消除阈值,并在本世纪末之前根除宫颈癌。